Citigroup Inc Xeris Biopharma Holdings, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Citigroup Inc holds 119,427 shares of XERS stock, worth $402,468. This represents 0.0% of its overall portfolio holdings.

Number of Shares

119,427

Previous 45,345 163.37%

Holding current value

$402,468

Previous $102,000 233.33%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$2.06 - $2.96 $152,608 - $219,282	74,082 Added 163.37%	119,427 $340,000
Q2 2024 Aug 12, 2024	BUY	$1.7 - $2.45 $6,091 - $8,778	3,583 Added 8.58%	45,345 $102,000
Q1 2024 May 10, 2024	BUY	$2.04 - $3.22 $40,428 - $63,813	19,818 Added 90.31%	41,762 $92,000
Q4 2023 Feb 09, 2024	BUY	$1.47 - $2.36 $29,616 - $47,546	20,147 Added 1121.15%	21,944 $51,000
Q3 2023 Nov 09, 2023	SELL	$1.8 - $2.69 $72,309 - $108,062	-40,172 Reduced 95.72%	1,797 $3,000
Q2 2023 Aug 10, 2023	BUY	$1.82 - $2.98 $73,564 - $120,451	40,420 Added 2609.43%	41,969 $109,000
Q1 2023 May 11, 2023	SELL	$1.03 - $1.63 $1,036 - $1,639	-1,006 Reduced 39.37%	1,549 $2,000
Q4 2022 Feb 09, 2023	SELL	$1.14 - $1.65 $1,136 - $1,645	-997 Reduced 28.07%	2,555 $3,000
Q3 2022 Nov 10, 2022	SELL	$1.37 - $1.93 $7,958 - $11,211	-5,809 Reduced 62.06%	3,552 $6,000
Q2 2022 Aug 10, 2022	SELL	$1.48 - $2.64 $482,167 - $860,082	-325,789 Reduced 97.21%	9,361 $14,000
Q1 2022 May 12, 2022	BUY	$2.0 - $2.87 $662,858 - $951,201	331,429 Added 8906.99%	335,150 $858,000
Q4 2021 Feb 10, 2022	BUY	$1.8 - $2.93 $6,697 - $10,902	3,721 New	3,721 $11,000

Others Institutions Holding XERS

# of Institutions

142

Shares Held

59.9M

Call Options Held

148K

Put Options Held

45.7K

View Full List

About Xeris Biopharma Holdings, Inc.

Ticker XERS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,956,992
Market Cap $458M
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...

More about XERS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account